Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Aditya Bardia, Allyson J. Ocean, Takefumi Komiya et al.|Annals of Oncology|2021

Cited by 371